Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.45 |
| ▸ | ADH1B | P00325 | 1/20 | 0.41 |
| ▸ | ADH1C | P00326 | 1/20 | 0.41 |
| ▸ | ADH1A | P07327 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1468324 | 1.00 | FDPS (0.45) | FDPSADH1BADH1CADH1ATSHR | |
| SCHEMBL601669 | 1.00 | FDPS (0.45) | FDPSADH1BADH1CADH1ATSHR | |
| SCHEMBL16149273 | 0.96 | FDPS (0.39) | FDPSADH1BADH1CADH1A | |
| SCHEMBL16149274 | 0.96 | FDPS (0.39) | FDPSADH1BADH1CADH1A | |
| SCHEMBL2276014 | 0.89 | SLC6A2 (0.38) | FDPSADH1BADH1CADH1ATSHR | |
| SCHEMBL555055 | 0.81 | ALDH1A1 (0.40) | ADH1BADH1CADH1ATSHRALDH1A1 | |
| SCHEMBL158232 | 0.81 | ALDH1A1 (0.40) | ADH1BADH1CADH1ATSHRALDH1A1 | |
| SCHEMBL11176992 | 0.79 | FDPS (0.50) | FDPSADH1BADH1CADH1AALDH1A1 | |
| SCHEMBL8407475 | 0.79 | ADH1B (0.38) | ADH1BADH1CADH1ATSHRALDH1A1 | |
| SCHEMBL997752 | 0.79 | ADH1B (0.38) | ADH1BADH1CADH1ATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3956348-A1 | PEPTIDE-BASED NON-PROTEINACEOUS CARGO DELIVERY | Feldan Bio Inc. (CA) | 2022-02-23 | — | — | EP | claimed |
| WO-2020210916-A1 | PEPTIDE-BASED NON-PROTEINACEOUS CARGO DELIVERY | FELDAN BIO INC. (CA) | 2020-10-22 | — | — | WO | claimed |
| WO-2008077194-A1 | RECEPTOR AGONISTS | XENOME LTD (AU) | 2008-07-03 | — | — | WO | claimed |
| EP-1466916-B1 | Peptide boronic acids useful in making salts thereof | TRIGEN LTD (GB) | 2007-10-24 | — | — | EP | claimed |
| EP-0984982-A1 | LH-RH PEPTIDE ANALOGUES, THEIR USES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LABORATOIRE THERAMEX (MC) | 2000-03-15 | — | — | EP | claimed |
| EP-4232590-A1 | SHUTTLE AGENT PEPTIDES OF MINIMAL LENGTH AND VARIANTS THEREOF ADAPTED FOR TRANSDUCTION OF CAS9-RNP AND OTHER NUCLEOPROTEIN CARGOS | Feldan Bio Inc. (CA) | 2023-08-30 | — | — | EP | disclosed |
| EP-4229207-A1 | PEPTIDE-BASED TRANSDUCTION OF NON-ANIONIC POLYNUCLEOTIDE ANALOGS FOR GENE EXPRESSION MODULATION | Feldan Bio Inc. (CA) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022082315-A1 | SHUTTLE AGENT PEPTIDES OF MINIMAL LENGH AND VARIANTS THEREOF ADAPTED FOR TRANSDUCTION OF CAS9-RNP AND OTHER NUCLEOPROTEIN CARGOS | FELDAN BIO INC. (CA) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022077121-A1 | PEPTIDE-BASED TRANSDUCTION OF NON-ANIONIC POLYNUCLEOTIDE ANALOGS FOR GENE EXPRESSION MODULATION | FELDAN BIO INC. (CA) | 2022-04-21 | — | — | WO | disclosed |
| US-20120190832-A1 | LOW-MOLECULAR SERINE PROTEASES INHIBITORS COMPRISING POLYHYDROXY-ALKYL AND POLYHYDROXY-CYCLOALKYL RADICALS | ABBOTT GMBH & CO. KG (DE) | 2012-07-26 | — | — | US | disclosed |
| EP-2456784-A1 | COMPOUNDS MODULATORS OF VEGF ACTIVITY AND USES THEREOF | Advanced Accelerator Applications S.A. (FR) | 2012-05-30 | — | — | EP | disclosed |
| US-20120040904-A1 | Boronate Medicaments for Preventing Thrombosis During Surgery | Trigen Holdings AG (GB) | 2012-02-16 | — | — | US | disclosed |
| EP-0796271-A1 | NEW DIPEPTIDE P-AMIDINOBENZYLAMIDES WITH N-TERMINAL SULFONYL OR AMINOSULFONYL RADICALS | BASF AKTIENGESELLSCHAFT (DE) | 1997-09-24 | — | — | EP | disclosed |
| WO-1996025426-A9 | NOVEL DIPEPTIDE AMIDINES AS THROMBIN INHIBITORS | — | 1997-06-12 | — | — | WO | disclosed |
| WO-1996024609-A1 | THROMBIN INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1996-08-15 | — | — | WO | disclosed |
| WO-1996017860-A1 | NEW DIPEPTIDE P-AMIDINOBENZYLAMIDES WITH N-TERMINAL SULFONYL OR AMINOSULFONYL RADICALS | BASF AKTIENGESELLSCHAFT (DE) | 1996-06-13 | — | — | WO | disclosed |
| US-5510369-A | ANTICOAGULANTS | MERCK & CO., INC. (US) | 1996-04-23 | — | — | US | disclosed |
| WO-1995035309-A1 | NEW THROMBIN INHIBITORS, THEIR PREPARATION AND USE | BASF AKTIENGESELLSCHAFT (DE) | 1995-12-28 | — | — | WO | disclosed |
| EP-0618926-A1 | NEW PEPTIDE DERIVATIVES | Astra Aktiebolag (SE) | 1994-10-12 | — | — | EP | disclosed |
| WO-1993011152-A1 | NEW PEPTIDE DERIVATIVES | AKTIEBOLAGET ASTRA (SE) | 1993-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040904-A1 | Boronate Medicaments for Preventing Thrombosis During Surgery | F9, FGB, TFPI | FDPS 1816/4885ADH1B 2996/4885ADH1C 2334/4885 |
| US-20120190832-A1 | LOW-MOLECULAR SERINE PROTEASES INHIBITORS COMPRISING POLYHYDROXY-ALKYL AND POLYHYDROXY-CYCLOALKYL RADICALS | F2R, C1R, PRSS1 | FDPS 3000/4885ADH1B 2465/4885ADH1C 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.